166 related articles for article (PubMed ID: 16291873)
1. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.
Perry M; Stansfeld PJ; Leaney J; Wood C; de Groot MJ; Leishman D; Sutcliffe MJ; Mitcheson JS
Mol Pharmacol; 2006 Feb; 69(2):509-19. PubMed ID: 16291873
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
3. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241.
Suessbrich H; Schönherr R; Heinemann SH; Lang F; Busch AE
FEBS Lett; 1997 Sep; 414(2):435-8. PubMed ID: 9315735
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of dofetilide block of HERG K+ channels.
Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
Varkevisser R; Houtman MJ; Linder T; de Git KC; Beekman HD; Tidwell RR; Ijzerman AP; Stary-Weinzinger A; Vos MA; van der Heyden MA
Br J Pharmacol; 2013 Jul; 169(6):1322-34. PubMed ID: 23586323
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of HERG channel block.
Kamiya K; Niwa R; Mitcheson JS; Sanguinetti MC
Mol Pharmacol; 2006 May; 69(5):1709-16. PubMed ID: 16474003
[TBL] [Abstract][Full Text] [Related]
8. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Ficker E; Obejero-Paz CA; Zhao S; Brown AM
J Biol Chem; 2002 Feb; 277(7):4989-98. PubMed ID: 11741928
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Hosaka Y; Iwata M; Kamiya N; Yamada M; Kinoshita K; Fukunishi Y; Tsujimae K; Hibino H; Aizawa Y; Inanobe A; Nakamura H; Kurachi Y
Channels (Austin); 2007; 1(3):198-208. PubMed ID: 18690032
[TBL] [Abstract][Full Text] [Related]
10. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
11. Open channel block of HERG K(+) channels by vesnarinone.
Kamiya K; Mitcheson JS; Yasui K; Kodama I; Sanguinetti MC
Mol Pharmacol; 2001 Aug; 60(2):244-53. PubMed ID: 11455010
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J; Gang H; Zhang S
J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
[TBL] [Abstract][Full Text] [Related]
13. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
[TBL] [Abstract][Full Text] [Related]
14. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
15. A structural basis for drug-induced long QT syndrome.
Mitcheson JS; Chen J; Lin M; Culberson C; Sanguinetti MC
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12329-33. PubMed ID: 11005845
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical features of the HERG channel drug binding site.
Fernandez D; Ghanta A; Kauffman GW; Sanguinetti MC
J Biol Chem; 2004 Mar; 279(11):10120-7. PubMed ID: 14699101
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
Sánchez-Chapula JA; Navarro-Polanco RA; Culberson C; Chen J; Sanguinetti MC
J Biol Chem; 2002 Jun; 277(26):23587-95. PubMed ID: 11960982
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E; Jarolimek W; Brown AM
Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
[TBL] [Abstract][Full Text] [Related]
20. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
Louvel J; Carvalho JF; Yu Z; Soethoudt M; Lenselink EB; Klaasse E; Brussee J; Ijzerman AP
J Med Chem; 2013 Dec; 56(23):9427-40. PubMed ID: 24224763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
